HER2 levels may aid in treatment selection for metastatic breast...

Courtesy EurekAlert! - Chemistry, Physics and Materials Sciences  Mon, 12/01/2008 - 23:00

(American Association for Cancer Research) Findings published in the Dec. 1, 2008, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit.

In addition, a misclassification of metastatic breast cancer patients by as much as 10 percent prevents some people from receiving optimal therapy.

Tags:

 

More related items

Team finds breast cancer gene linked to disease spread
(Princeton University) A team of researchers at Princeton University and The Cancer Institute of New Jersey has identified a long-sought gene that is fatefully switched on in 30 to 40 percent...

Early Stage, HER2-positive Breast Cancer Patients At...
Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared to those with early-stage disease who...

Cancer Treatment: Selecting Patients Based On...
Breast cancer patients who carry the wild-type gene required for tamoxifen metabolism may have comparable risk of recurrence when taking tamoxifen or an aromatase inhibitor, according to...

HP 50g Graphing Calculator (F2229AA#ABA)
If you're a math, science, or engineering professional?or a serious college student?don't leave home without it! HP's most powerful new graphing calculator. The 50G supplies you with...

Kitchen Mysteries: Revealing the Science of Cooking...
An international celebrity and founder of molecular gastronomy, or the scientific investigation of culinary practice, Herv& eacute; This is known for his ground-breaking research into the...


 

Post new comment

The content of this field is kept private and will not be shown publicly.
science-nature.marc8.com